About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
PhRMA submitted a pre-hearing brief to the U.S. International Trade Commission (USITC) concerning its Section 332 investigation titled “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities.” The innovative biopharmaceutical industry worked around the clock to research, develop and deploy vaccines and therapeutics to treat and prevent infections from the novel coronavirus and associated conditions – all while maintaining the supply of existing treatments and vaccines and developing new medicines for other diseases. This brief details the significant risks from the TRIPS waiver that undermine pandemic response and future preparedness.
"PhRMA Comments to USITC on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities" image
Comment
Policy Paper
PhRMA Comments to USITC on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
"PhRMA Comments to USITC on COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities" image